Lakefront Biotherapeutics NV current report, Q3 FY2022

Business Context and Reporting Period

This Form 6-K filing is submitted by Galapagos NV, a foreign private issuer, for the month of September 2022. The filing, dated September 27, 2022, serves to incorporate by reference a press release (Exhibit 99.1) issued on the same date. The registrant files annual reports under Form 20-F. Note: While the request metadata mentions "Lakefront Biotherapeutics NV," the filing text explicitly identifies the registrant as Galapagos NV.

Key Financial Metrics

The filing text provided does not contain specific financial data. It is a procedural filing to distribute a press release and does not include revenue, profit, cash flow, margins, debt, or liquidity figures.

Material Changes

The filing text does not provide details on material changes versus prior periods. The content is limited to the administrative incorporation of a press release into the company's registration statements.

Guidance, Outlook, and Risks

The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or unusual items. These details would be contained within the attached press release (Exhibit 99.1), the text of which is not included in the provided input.

Investor Verification Checklist

  • Verify the specific content of the press release dated September 27, 2022 (Exhibit 99.1), as the filing itself contains no operational or financial details.
  • Confirm the registrant identity is Galapagos NV, not Lakefront Biotherapeutics NV, based on the official filing text.
  • Review the referenced Registration Statements on Form S-8 (File Nos. 333-204567 through 333-260500) for context on how this press release impacts existing equity plans.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.